EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

London-listed GSK Plc and France’s Sanofi SA saw similar declines ... lead a sprawling federal department that encompasses ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses.

The current US Supreme Court has no fundamental understanding of a range of medical, engineering, technological, or ...

Brad Lightcap, COO, OpenAI "We believe AI can accelerate drug development, bringing new treatments to patients more quickly. This first product from our collaboration with Sanofi and Formation Bio is ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Powered by PandaOmics, Insilico’s proprietary generative biology AI platform, the joint R&D team comprising Insilico Medicine and Sanofi colleagues focused on highly novel targets known to be ...